Compare Moderna, Inc. (MRNA) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Xpeng Inc - ADR — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: Moderna, Inc. is far larger — about 8.6× Xpeng Inc - ADR's market cap, and Moderna, Inc. is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Xpeng Inc - ADR for 80 Days on average.
| MRNA | XPEV | |
|---|---|---|
Market Cap | $78.65B | $9.16B |
Volume | 37,373,437 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $225.00 | $28.07 |
52-Week Low | $22.36 | $9.25 |
Typical Hold Time | 59 Days | 80 Days |
Enterprise Value | $74.80B | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
XPeng (XPEV) trades at $9.55, down 0.31% with a bearish technical signal. The company shows strong revenue growth to $76.72B in 2025 but remains unprofitable with a net margin of -4.14%. Recent vehicle deliveries of 41,256 in September 2026 and the upcoming G9L SUV launch at the Paris Motor Show highlight expansion efforts. Analyst consensus is bullish with a $17.55 price target, though earnings misses in Q1 and Q2 2026 raise execution concerns.
The stock presents a high-risk, high-reward opportunity. Significant revenue growth and analyst optimism are offset by persistent losses and competitive pressures. Key catalysts include successful global expansion and profitability improvements, while risks involve execution missteps and macroeconomic headwinds in the EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
